BostonGene
PrivateLast Round
Series B
Apr 6, 2022
Est. Valuation
$2B
Total Funding Raised
$200M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
BostonGene operates in Healthcare & Life Sciences and is based in Waltham, Massachusetts. Its latest recorded funding round was a Series B round in April 2022.
BostonGene is a biotechnology company that develops an AI-powered, omnimodal analysis platform that integrates genomic, transcriptomic, immune, and clinical data to provide actionable insights for oncology drug development and personalized patient care.
Sector
Healthcare & Life Sciences
Verticals
Precision Medicine, Biotechnology, Healthcare Analytics, Medical AI, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Foundation
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BostonGene Comparables
Compare BostonGene with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Tempus | 83% | |
| Caris Life Sciences | 80% | |
| ConcertAI | 76% |
For institutional investors. Book with your work email.
BostonGene Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Apr 6, 2022 | ||||
| Series A | Apr 24, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
BostonGene Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Japan Industrial Partners | Series B |
| Impact Investment Exchange | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 6, 2026
Showcased AI technology at ACR Convergence 2026 conference.
- Aug 21, 2026
Monthly visitors grew 55% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventNov 6, 2026
BostonGene Corporation showcases biologically grounded AI at ACR Convergence 2026, held Nov 6th-11th '26 in Florida, to advance precision rheumatology and autoimmune disease stratification.
- receives_awardNov 3, 2026
BostonGene Corporation receives three Gold Stevie(R) Awards from the 2026 Stevie(R) Awards for Technology Excellence in Massachusetts on Nov 3rd '26, earning Company of the Year, New Product of the Year, and Technology Breakthrough of the Year honors in Biotechnology for its AI modeling of how tumors and immune systems respond to therapy.
- recognized_asNov 3, 2026
On Nov 3rd '26 in Massachusetts, the Stevie Awards for Technology Excellence awards BostonGene Corporation three Gold Stevie Awards in the 2026 Stevie Awards for Technology Excellence, including top honors as Company of the Year, New Product of the Year, and Technology Breakthrough of the Year in Biotechnology.
- attends_eventOct 27, 2026
BostonGene Corporation’s CCO Ferran Prat is set to moderate the “Ecosystem of External Innovation” panel at the Longwood Healthcare Leaders Boston CEO conference in Massachusetts on Nov 2nd '26.
- partners_withOct 20, 2026
BostonGene Corporation and MUSC Enterprise announce a strategic research collaboration in Massachusetts on Oct 20th '26 to advance CAR-T therapy insights for lymphoma and leukemia using biologically grounded AI and multimodal immune-system profiling.
For institutional investors. Book with your work email.
BostonGene Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about BostonGene's valuation, stock price, and market status.
Is BostonGene a public or private company?
BostonGene is a private company.
What is the current stock price of BostonGene?
BostonGene is a private company, so its shares have no public market price. Caplight tracks BostonGene's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is BostonGene worth (valuation)?
BostonGene's valuation is estimated at $2.0B based on funding round data.
Can I buy BostonGene stock?
BostonGene shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was BostonGene's last funding round?
BostonGene's most recent funding round was Series B on April 6, 2022.
Who are the main investors in BostonGene?
Key investors in BostonGene include Japan Industrial Partners, Impact Investment Exchange.
Will BostonGene IPO soon?
No public IPO plans have been announced for BostonGene.
How can I track BostonGene secondary market activity?
Caplight tracks bids, offers, and trades in BostonGene's shares on secondary markets.